Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
about
Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progressionMatrix metalloproteinases, T cell homing and beta-cell mass in type 1 diabetes.Matrix metalloproteinase biology applied to vitreoretinal disorders.Envelope gene-mediated neurovirulence in feline immunodeficiency virus infection: induction of matrix metalloproteinases and neuronal injury.Basis for substrate recognition and distinction by matrix metalloproteinasesTargeting Neovascularization in Ischemic Retinopathy: Recent AdvancesSubstrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface.Rapid vascular regrowth in tumors after reversal of VEGF inhibition.Somatic antigens of tropical liver flukes ameliorate collagen-induced arthritis in wistar ratsMMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16(INK4a) and mitogen-activated protein kinase pathway.Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.Molecular optical imaging: applications leading to the development of present day therapeuticsMatrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein sheddingCombined upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 predicts unfavorable prognosis in human nasopharyngeal carcinoma.Targeting angiogenesis for treatment of human cancerAnti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model.Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.Doublecortin induces mitotic microtubule catastrophe and inhibits glioma cell invasion.Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma
P2860
Q31101634-DD85D0E8-0108-486B-AFFC-A42CF6AB8DFDQ33732496-38BF891B-BB95-4B1A-9B5C-61372DA7977AQ33797703-6856FD22-7C18-4538-9394-11668CD22EA8Q33933063-660E8273-A498-4F5E-931F-BEDF8E08CF8CQ34332239-8693464C-4C37-47A9-BEAC-04732EFFEBD7Q34407655-CB3DBD98-F066-4D1F-8339-8E765BDA101EQ34972210-29F3AA0D-6E8B-4378-B78D-2AD256A161DCQ35021987-0E026718-0B41-4F33-96DB-10DDE39D165BQ35052385-301968DB-ACDE-4A03-90E2-003169A0A3D4Q35620689-62336F41-47E0-4090-9449-E63E99EC8BDFQ35867473-F2F0DAB8-4864-4061-909A-9D4C7D57E5C9Q36009930-15158588-72F6-42E4-A93A-B2D79ECFA414Q36020841-DD450B6A-CC51-4D68-8069-0F5601E8905DQ36129726-9C160C0D-D7B2-4AB0-8E6E-2C5A83BF7C87Q36644577-290CE31D-761C-42C2-A147-2FF19968440BQ36804675-D9D05B16-35C3-4158-B3E1-A1A7884536B1Q37125603-F88C0A7C-E596-4FE3-9D76-2D127307384BQ38125442-9A9A1A99-E412-4400-8207-DED7E51B628AQ38282828-739637F1-13B1-4BD0-95B7-5559ED2E7330Q39049177-1A11087E-2C1F-48E1-A696-8CBF0605AD24Q39903803-5E54CACB-6C6D-413A-94CC-59AE079F4B8AQ59034785-6A7812C0-39D7-4D56-9FEE-EB557197363B
P2860
Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Broad antitumor and antiangiog ...... anced oncology clinical trials
@ast
Broad antitumor and antiangiog ...... anced oncology clinical trials
@en
Broad antitumor and antiangiog ...... anced oncology clinical trials
@nl
type
label
Broad antitumor and antiangiog ...... anced oncology clinical trials
@ast
Broad antitumor and antiangiog ...... anced oncology clinical trials
@en
Broad antitumor and antiangiog ...... anced oncology clinical trials
@nl
prefLabel
Broad antitumor and antiangiog ...... anced oncology clinical trials
@ast
Broad antitumor and antiangiog ...... anced oncology clinical trials
@en
Broad antitumor and antiangiog ...... anced oncology clinical trials
@nl
P2093
P1476
Broad antitumor and antiangiog ...... anced oncology clinical trials
@en
P2093
C D McDermott
D R Shalinsky
P304
P407
P577
1999-06-30T00:00:00Z